These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38905044)

  • 41. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dual-Task Performance and Neurodegeneration: Correlations Between Timed Up-and-Go Dual-Task Test Outcomes and Alzheimer's Disease Cerebrospinal Fluid Biomarkers.
    Åhman HB; Giedraitis V; Cedervall Y; Lennhed B; Berglund L; McKee K; Kilander L; Rosendahl E; Ingelsson M; Åberg AC
    J Alzheimers Dis; 2019; 71(s1):S75-S83. PubMed ID: 31104024
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Underlying Biological Processes in Mild Cognitive Impairment: Amyloidosis Versus Neurodegeneration.
    Santana I; Baldeiras I; Santiago B; Duro D; Freitas S; Pereira MT; Almeida MR; Oliveira CR
    J Alzheimers Dis; 2018; 64(s1):S647-S657. PubMed ID: 29562515
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Free and Cued Selective Reminding Test is superior to the Wechsler Memory Scale in discriminating mild cognitive impairment from Alzheimer's disease.
    Lemos R; Cunha C; Marôco J; Afonso A; Simões MR; Santana I
    Geriatr Gerontol Int; 2015 Aug; 15(8):961-8. PubMed ID: 25243721
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cerebrospinal fluid biomarkers and memory present distinct associations along the continuum from healthy subjects to AD patients.
    Rami L; Fortea J; Bosch B; Solé-Padullés C; Lladó A; Iranzo A; Sánchez-Valle R; Molinuevo JL
    J Alzheimers Dis; 2011; 23(2):319-26. PubMed ID: 21098971
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Linking CSF and cognition in Alzheimer's disease: Reanalysis of clinical data.
    Guhra M; Thomas C; Boedeker S; Kreisel S; Driessen M; Beblo T; Ohrmann P; Toepper M
    Exp Gerontol; 2016 Jan; 73():107-13. PubMed ID: 26585048
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CSF Aβ
    Rizzi L; Missiaggia L; Roriz-Cruz M
    Neuromolecular Med; 2018 Dec; 20(4):491-497. PubMed ID: 30306396
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults.
    Popp J; Oikonomidi A; Tautvydaitė D; Dayon L; Bacher M; Migliavacca E; Henry H; Kirkland R; Severin I; Wojcik J; Bowman GL
    Brain Behav Immun; 2017 May; 62():203-211. PubMed ID: 28161476
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes.
    Carandini T; Arighi A; Sacchi L; Fumagalli GG; Pietroboni AM; Ghezzi L; Colombi A; Scarioni M; Fenoglio C; De Riz MA; Marotta G; Scarpini E; Galimberti D
    Alzheimers Res Ther; 2019 Oct; 11(1):84. PubMed ID: 31615545
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In Brief Neuropsychological Assessment, Amnestic Mild Cognitive Impairment (MCI) Is associated with Cerebrospinal Fluid Biomarkers for Cognitive Decline in Contrast to the Prevailing NIA-AA MCI Criterion.
    Hessen E; Kirsebom BE; Eriksson CM; Eliassen CF; Nakling AE; Bråthen G; Waterloo KK; Aarsland D; Fladby T
    J Alzheimers Dis; 2019; 67(2):715-723. PubMed ID: 30614807
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prodromal Alzheimer's Disease: Global Cognition, Cue Efficiency, and Cerebrospinal Fluid Neurofilament Light Values Predict Short-Term Conversion to Dementia.
    Méndez-Barrio C; Medina-Rodríguez M; Mendoza-Vázquez G; García-Roldán E; Rodrigo-Herrero S; Luque-Tirado A; Almodóvar-Sierra Á; Franco-Macías E
    J Alzheimers Dis; 2024; 101(3):877-887. PubMed ID: 39302377
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 53. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change.
    Vemuri P; Wiste HJ; Weigand SD; Shaw LM; Trojanowski JQ; Weiner MW; Knopman DS; Petersen RC; Jack CR;
    Neurology; 2009 Jul; 73(4):294-301. PubMed ID: 19636049
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease.
    Alcolea D; Carmona-Iragui M; Suárez-Calvet M; Sánchez-Saudinós MB; Sala I; Antón-Aguirre S; Blesa R; Clarimón J; Fortea J; Lleó A
    J Alzheimers Dis; 2014; 42(1):157-67. PubMed ID: 24820015
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Association of APOE genotype and cerebrospinal fluid Aβ and tau biomarkers with cognitive and motor phenotype in amyotrophic lateral sclerosis.
    Maranzano A; Verde F; Dubini A; Torre S; Colombo E; Doretti A; Gentile F; Manini A; Milone I; Brusati A; Peverelli S; Santangelo S; Spinelli EG; Torresani E; Gentilini D; Messina S; Morelli C; Poletti B; Agosta F; Ratti A; Filippi M; Silani V; Ticozzi N
    Eur J Neurol; 2024 Sep; 31(9):e16374. PubMed ID: 38853763
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Brain metabolism and cerebrospinal fluid biomarkers profile of non-amnestic mild cognitive impairment in comparison to amnestic mild cognitive impairment and normal older subjects.
    Coutinho AM; Porto FH; Duran FL; Prando S; Ono CR; Feitosa EA; Spíndola L; de Oliveira MO; do Vale PH; Gomes HR; Nitrini R; Brucki SM; Buchpiguel CA
    Alzheimers Res Ther; 2015 Sep; 7(1):58. PubMed ID: 26373380
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Usefulness of CSF Biomarkers in Predicting the Progression of Amnesic and Nonamnesic Mild Cognitive Impairment to Alzheimer's Disease.
    Ortega RL; Dakterzada F; Arias A; Blasco E; Naudí A; Garcia FP; Piñol-Ripoll G
    Curr Aging Sci; 2019; 12(1):35-42. PubMed ID: 31589110
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
    Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
    J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.
    Stav AL; Aarsland D; Johansen KK; Hessen E; Auning E; Fladby T
    Parkinsonism Relat Disord; 2015 Jul; 21(7):758-64. PubMed ID: 25971633
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CSF markers of AD-related pathology relate specifically to memory impairment in older people with HIV: a pilot study.
    Lobo JD; Moore DJ; Bondi MW; Soontornniyomkij V; Soontornniyomkij B; Gouaux B; Achim CL; Ellis RJ; Sundermann EE
    J Neurovirol; 2022 Feb; 28(1):162-167. PubMed ID: 35103880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.